tbuckley/cabot-search huggingface dataset:
Dr. Scott Did Not Resign from Veterans' Bureau.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B– and C–related risk
Authors: M Yu
Journal: Hepatology (2003)

Hepatocellular carcinoma (HCC) is more prevalent in men than in women. Estrogen may play some role in the development of HCC. We conducted a multicenter case-control study to evaluate the effects of reproductive factors on HCC risk, and to assess whether the association between each factor and HCC differs between hepatitis B surface antigen (HBsAg)-positive and -negative women, in which hepatitis C virus (HCV) is the major cause of HCC. The study included 218 women with HCC and 729 control women selected from nonbiological and first-degree female relatives of patients with HCC. The risk of HCC was inversely related to the number of full-term pregnancies (FTP) (Ptrend = .0216) and age at natural menopause (Ptrend = .0251 among women aged 45-55 without prior surgical menopause). Oophorectomy at age ≤50 during premenopausal years was also a risk factor (multivariate-adjusted OR, 2.57; 95% CI, 1.42-4.63). Use of hormone replacement therapy (HRT) (multivariate-adjusted OR, 0.46; 95% CI, 0.27-0.79) was associated with a lower risk of HCC, and there was a trend in the risk with increasing duration of HRT (Ptrend = 0.0013). All reproductive factors had a similar impact on HBsAg-positive and -negative women except for an early menarche (≤12 vs. ≥16 years), which increased HCC risk in HBsAg carriers (multivariate-adjusted OR, 6.96; 95% CI, 2.52-19.18) but posed no increased risk in noncarriers (Pinteraction = .0053). In conclusion, increased exposure to estrogen during adulthood may provide a protective effect against HCC. Nevertheless, an early menarche, which results in early estrogen exposure, does not confer protection for HBsAg carriers. (Hepatology 2003;38:1393-1400.)
Oncogenic Viruses
Authors: Bernice E. Eddy
Journal: JAMA (1971)

Dr. Gross, a pioneer in the field of cancer research, has succeeded admirably in organizing and recording basic information on oncogenic viruses and the tumors which they induce. The present text continues the excellent trend begun in 1961 when the first volume of this projected work appeared. The 935-page current edition of his earlier 375-page book reflects the changes and advances in experimental cancer research as it relates to viruses. The chapters on Rous sarcoma, chicken leukosis, and mouse leukemias have been completely revised and enlarged. New chapters on oncogenic viruses isolated since 1961 have been added. The mouse osteosarcoma virus, the mouse sarcoma virus, and viruses causing leukemia or lymphosarcoma in cats, dogs, and guinea pigs have been described. New chapters on bovine leukosis, simian virus 40, and the oncogenic potentials of human, simian, avian, and bovine adenoviruses have been added. A chapter is devoted to information on the
Polyarteritis and intrarenal renal artery aneurysms
Authors: L. Dornfeld
Journal: JAMA (1971)

The diagnosis of polyarteritis nodosa is frequently difficult. Renal biopsy is often hazardous due to severe hypertension or azotemia. Renal arteriographic changes described herein are considered specific for polyarteritis nodosa. These include intrarenal renal artery aneurysms confined to the distal segmental, interlobar, and occasionally the arcuate arteries.
Differential expression of hepatocyte growth factor, transforming growth factor-α and transforming growth factor-β1 messenger RNAs in two experimental models of liver cell proliferation
Authors: M Masuhara
Journal: Hepatology (1992)

Hepatocyte growth factor, a potent hepatocyte mitogen in vitro, appears to trigger hepatocyte regeneration after partial hepatectomy and after acute liver cell necrosis. Transforming growth factor-α and transforming growth factor-β may also be involved in the control of liver regeneration. In this study we assessed possible roles of hepatocyte growth factor, transforming growth factor-α and transforming growth factor-β1 on liver cell proliferation in vivo, using a model of choline deficiency that is associated with liver cell necrosis and a model of a hypolipidemic agent (4-chloro-6-(2,3 xylidino)-2-pyrimidinylthio (N-β-hydroxyethyl) acetamide) without liver necrosis. Male F344 rats were fed a choline-deficient diet or 0.16% 4-chloro-6-(2,3 xylidino)-2-pyrimidinylthio (N-β-hydroxyethyl) acetamide diet for 6 and 4 wk, respectively. Rats were killed periodically, and the expression of hepatocyte growth factor messenger RNA in the liver, lung and kidney was determined by Northern-blot analysis. The levels of transforming growth factor-α and transforming growth factor-β1 messenger RNAs in the liver were also determined. Feeding a choline-deficient diet for 1 to 6 wk led to gradual increases in the levels of hepatocyte growth factor, transforming growth factor-α and transforming growth factor-β1 messenger RNAs in the liver. Feeding a 4-chloro-6-(2,3 xylidino)-2-pyrimidinylthio (N-β-hydroxyethyl) acetamide diet for 3 days and 2 wk induced marked enhancement of liver cell proliferation as judged by hepatocyte 5-bromo-2-deoxyuridine incorporation. In contrast to the choline-deficient diet-induced liver cell proliferation, 4-chloro-6-(2,3 xylidino)-2-pyrimidinylthio (N-β-hydroxyethyl) acetamide-induced liver cell proliferation was associated with decreased levels of hepatocyte growth factor and transforming growth factor-β1 messenger RNAs. Feeding of a cholinedeficient diet or 4-chloro-6-(2,3 xylidino)-2-pyrimidinylthio (N-β-hydroxyethyl) acetamide had no apparent effects on the levels of hepatocyte growth factor messenger RNA in the lung and kidney. The results suggest that distinct patterns of messenger RNA expression exist for the growth factors in the liver undergoing compensatory hyperplasia and mitogenic stimulation of liver cell proliferation and that the role of hepatocyte growth factor in liver cell proliferation in vivo depends on the nature of the proliferative stimuli. (HEPATOLOGY 1992;16:1241–1249.)
Certain Prescribing Patterns Lead to Long-term Opioid Use
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Varia
Authors: R. Le Coultre, Paul J. Reiter, Heinrich Huebschmann, Ernst Schneider, H.-J. Schumann, F. Pollak, Ferruccio Antonelli, Alice Friedman, Henri Foissin, L. Navratil, E. Kriehüber, R. Wenger
Journal: Psychotherapy and Psychosomatics (1956)
APOE基因的多重效应:中国西南部地区的汉族人中的APOE多态性与多菌型麻风病的关联
Authors: D. Wang, D.-F. Zhang, G.-D. Li, R. Bi, Y. Fan, Y. Wu, X.-F. Yu, H. Long, Y.-Y. Li, Y.-G. Yao
Journal: British Journal of Dermatology (2018)

Summary 本项研究由来自中国科学院和中国云南省一些皮肤科的研究人员共同执行。本项研究以早前的观察为基础,该项观察发现,麻风病患者患上因阿尔茨海默病而导致的痴呆的频率低于未患有麻风病的患者,因此,研究人员旨在研究麻风病的发病与不同油脂和脂肪的形成与分解中所涉及的人类基因之间是否存在关联,而这些过程是阿尔茨海默病的发展和麻风病的皮肤和神经侵袭中的关键步骤。他们研究了被称为载脂蛋白E (APOE)的基因(在阿尔茨海默病中涉及)之间的关联,然后发现该基因中的某些突变在麻风病患者中更为常见。他们建议,这可能会导致血浆中脂质结合蛋白质的增加,并转而有助于导致麻风病的细菌(麻风分枝杆菌)的存活,因而细菌继续扩散并导致疾病的发展。
Outbreak of Influenza A in a Nursing Home —New York, December 1991-January 1992
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Lymphocyte Function-Associated Lfa-1, Cd2, And Lfa-3 Molecules: Cell Adhesion Receptors Of The Immune System
Authors: T. Springer
Journal: Annual Review of Immunology (1987)

Exhausted CD8 T (Tex) cells are a distinct cell lineage that arise during chronic infections and cancers in animal models and humans. Tex cells are characterized by progressive loss of effector functions, high and sustained inhibitory receptor expression, ...Read More
REPORT ON CLINICAL LABORATORY SERVICE IN THE UNITED STATES
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Appendicitis.
Authors: John F. Burns
Journal: JAMA (1898)

Long Island City, June 7, 1898. <h3>To the Editor:</h3> —I have read with interest Dr. J. F. Baldwin's paper on "Some Unusual Cases of Appendicitis," in theJournalof June 4, 1898, and particularly struck by his reference to the case of complicating general peritonitis (purulent) and his remarks thereon, and reference to Dr. Abbe's statement that the maximum limit of expectancy from an operative standpoint in these cases might be placed at two and one-half days. I have had a number of operative cases of such a character that would tend to substantiate this proposition as a certainty, yet have had several which would negative it, at least in individual cases. Thinking that it might encourage others to persevere even in very desperate cases of this character, I beg to report the following case, which is the most positive and the facts of which are the clearest in my
Pain Relief
Authors: Carolyn J. Hildreth
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SOCIOLOGIC REFORMS.
Authors: ARTHUR R. REYNOLDS
Journal: JAMA (1897)

The Board of State Commissioners of Public Charities were moved to call this conference, feeling that there was a growing demand for knowledge of our institutions, and an increasing interest in the care of dependent persons. There seems, also, to be an awakening among charitably inclined people, as to how best to help those who can not help themselves. It is true, that our board publishes every two years a report of their doings, so also do the larger institutions, but they are read by comparatively few persons. The amount of money paid out directly by the State, to support persons unfitted by nature or disease to support themselves, is very large, but when we come to consider the amount expended by the several counties and municipalities, and the sums subscribed, through churches and other public bodies of organized charity, together with the amount expended in private work, of the
Missing Points in Figure
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FOTHERGILL, THE QUAKER PHYSICIAN OF LONDON
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers
Authors: R. J. Kim, G. Peterson, B. Kulp, K. M. Zanotti, M. Markman
Journal: Journal of Clinical Oncology (2004)

5080 Background: Pegylated liposomal doxorubicin (PLD) is a chemotherapeutic agent used in the management of myriad gynecologic cancers. Although it is proposed to have less side effects than doxorubicin, PLD is associated with significant skin reactions. The incidence of skin toxicity of PLD administered at a lower dose (40 mg/m2) is not well-characterized. Methods: Medical charts of all patients who initiated PLD at a starting dose of 40 mg/m2 from 1997–2003 for the treatment of gynecologic cancers were retrospectively reviewed. PLD was infused over 1–2 hours and administered every 4–6 weeks. No patient had previously received doxorubicin. All patients were clinically assessed for adverse reactions including skin toxicity. Results: 90 patients (mean age 62 yrs, range 45–82 yrs) were included in this analysis. There were 55 ovarian, 16 endometrial, 2 fallopian, and 17 primary peritoneal cancers. The median cumulative dose of PLD was 100 mg/m2 (range 40–855 mg/m2) with a median of 3 cycles (range 1–25). 33/90 (37%) developed a skin reaction during therapy. The overall incidence of grade 1, 2, and 3 skin toxicity was 23 (26%), 9 (10%), and 1 (1%), respectively. Of the 23 cases of grade 1 toxicity, 16 (70%) occurred within 1–3 cycles. All 9 cases of grade 2 toxicity occurred within 1–3 cycles. The only case of grade 3 toxicity occurred after the first cycle. 28/30 (93%) patients who continued treatment did not experience further episodes of skin toxicity with subsequent cycles after a dose reduction (5–20 mg/m2). PLD was stopped in only 2/90 (2%) cases due to a skin reaction. Conclusions: Severe skin toxicity (≥grade 2) associated with PLD occurs infrequently when initial doses of 40 mg/m2 are administered. When skin reactions appear, they usually occur early in the course of treatment, respond to dose reduction, and do not appear to limit the duration of treatment. No significant financial relationships to disclose.
Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Final results of the prospective multicentre non-interventional RECORA study.
Authors: Holger Schulz, Jan Janssen, Uwe P. Strauss, Markus Langen, Kai Uwe Dworschak, Sabine Fiala-Buskies, Carsten Bokemeyer
Journal: Journal of Clinical Oncology (2018)

748 Background: In 2013 REG was approved for mCRC based on the results achieved in the CORRECT trial. However, prospective data from daily practice use are still scarce. Methods: RECORA investigated efficacy and safety of REG in routine clinical care in Germany. Male/female mCRC patients (pts) ≥ 18 years for whom the decision was taken to treat with REG in its approved indication were enrolled. Primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival time (PFS), time-to-progression (TTP), disease control rate (DCR), and incidence of treatment-emergent adverse events (TEAE). Subgroup analyses for OS, PFS, TTP and safety were performed according to age, sex, ECOG PS, KRAS status, time from initial diagnosis, number of prior bevacizumab therapies, tumor location, and sites of metastases (mets). Results: 481 pts were enrolled at 90 sites between 10/13 and 07/16; 464 pts were included in the safety analysis, 463 for efficacy. Mean/median age was 67 years (range 30-89), 60% of pts were male, baseline ECOG PS was 0 in 20%, 1 in 61%, 2 in 18%, and 3 in 1% of pts, 63% had a primary colon cancer, 46% had KRAS mutated tumors at diagnosis, 75% had mets in the liver, 59% in the lung , and 42% in both lung and liver. Median OS was 5.8 months (mos) (95% CI 5.3-6.6), median PFS was 3.1 mos (95% CI 2.8-3.3), median TTP was 4.0 mos (95% CI 3.6-4.9), DCR was 26.7%. There were no significant differences in OS in subgroups according to age ( &lt; 65/≥65), sex, KRAS status, prior bevacizumab therapy, and primary tumor site; whereas OS was significantly different in subgroups according to ECOG PS (ECOG 0/1 vs. 2) and time from initial diagnosis ( &lt; 18/≥18 mos). TEAE grade ≥3 occurred in 57.5% of pts, in 19% REG related. A serious TEAE was recorded in 51% of pts, in 9% considered as REG related. Overall, 29% died of an AE, in 0.4% REG related. 24.4% of pts received further anti-tumor therapy after REG was stopped. Conclusions: RECORA, a non-interventional real-life setting study, showed clinical benefit and acceptable tolerability for REG in this final analysis. The OS achieved was in the same range as in the pivotal study. Clinical trial information: NCT01959269.